Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ostrava
Clinical trial register · Czechia

Clinical Trials in Ostrava, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Czechia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1513 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:18 UTC
1513
Studies in scope
all four open statuses
780
Recruiting now
open to new participants
300
Lead sponsors
across recruiting studies
Top sites
Prague 1080 Brno 610 Hradec Králové 323 Olomouc 313 Ostrava 282
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Hospital Ostrava29 Eli Lilly and Company25 Merck Sharp & Dohme LLC16 Janssen Research & Development, LLC16 Sanofi14 AbbVie12 Novartis Pharmaceuticals12 AstraZeneca9 Bristol-Myers Squibb9 Pfizer8 Takeda8 European Myeloma Network B.V.5 University of Ostrava4 Ipsen4 Hoffmann-La Roche4 BeOne Medicines4 Genmab3 MoonLake Immunotherapeutics AG3 Amgen3 Incyte Corporation3 Ascentage Pharma Group Inc.2 ADC Therapeutics S.A.2 Gilead Sciences2 Bluefin Biomedicine, Inc.2 CSL Behring2 argenx2 Institut de Recherches Internationales Servier2 Regeneron Pharmaceuticals2 Kartos Therapeutics, Inc.2 GlaxoSmithKline2 Stichting European Myeloma Network2 Charles University, Czech Republic2 Stimvia s.r.o.1 Morten H. Bestle1 Tenax Therapeutics, Inc.1 Womed1 Alumis Inc1 Rigel Pharmaceuticals1 Masaryk University1 M.A. Med Alliance S.A.1 BioNTech SE1 NovoCure GmbH1 Dianthus Therapeutics1 Seagen, a wholly owned subsidiary of Pfizer1 Abivax S.A.1 Menarini Group1 Taiho Oncology, Inc.1 Almirall, S.A.1 Alnylam Pharmaceuticals1 IO Biotech1 North Eastern German Society of Gynaecological Oncology1 Draig Therapeutics Ltd1 The Institute of Molecular and Translational Medicine, Czech Republic1 Abcentra1 SystImmune Inc.1 University of Zurich1 University Hospital Olomouc1 Dizal Pharmaceuticals1 Genentech, Inc.1 Belite Bio, Inc1 Sanofi Pasteur, a Sanofi Company1 Institut Claudius Regaud1 Loxo Oncology, Inc.1 Immunovant Sciences GmbH1 Teva Branded Pharmaceutical Products R&D LLC1 Karyopharm Therapeutics Inc1 Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany1 TG Therapeutics, Inc.1 COMPASS Pathways1 medac GmbH1 Stichting Hemato-Oncologie voor Volwassenen Nederland1 Biogen1 Servier Bio-Innovation LLC1 Agios Pharmaceuticals, Inc.1 Novo Nordisk A/S1 Spyre Therapeutics, Inc.1 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS1 St. Anne's University Hospital Brno, Czech Republic1 Ionis Pharmaceuticals, Inc.1 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company1 UCB Biopharma SRL1 Institute for Clinical and Experimental Medicine1 Czech Lymphoma Study Group1 Tomas Bata Hospital, Czech Republic1 KARDI AI Technologies s.r.o.1 University of Regensburg1 Philip Morris Products S.A.1 BTL Industries Ltd.1 Miltenyi Biomedicine GmbH1 Ono Pharmaceutical Co., Ltd.1 Institute of Health Information and Statistics of the Czech Republic1 Swedish Orphan Biovitrum1 Alfasigma S.p.A.1 Apollo Therapeutics Ltd1 Mirati Therapeutics Inc.1 Alexion Pharmaceuticals, Inc.1 University Hospital, Gasthuisberg1 Merz Pharmaceuticals GmbH1 Triveni Bio1
Site location
Prague1080 Brno610 Hradec Králové323 Olomouc313 Ostrava282 Pilsen117 Pardubice92 České Budějovice61 Zlín47 Nový Jičín45 Uherské Hradiště38 Liberec36 Náchod33 Ústí nad Labem33 Ostrava - Poruba32 Ostrava-Poruba32 Brandýs nad Labem30 Jihlava29 Teplice26 Hořovice24 Slaný17 Hodonín16 Kladno15 Hlučín14 Choceň14 Jindřichův Hradec14 Český Krumlov14 Rychnov nad Kněžnou13 Chlumec nad Cidlinou13 Broumov13 Havířov13 Benešov12 Krnov12 Třinec10 Mladá Boleslav9 Opava8 Klecany8 Kutná Hora7 Kralupy nad Vltavou7 Varnsdorf7 Jaroměř7 Louny7 Mariánské Lázně7 Kolín6 Havlíčkův Brod6 Jablonec nad Nisou6 Příbram6 Klatovy6 Ostrava-Vitkovice5 Bruntál5 Chomutov5 Ostrava - Vitkovice5 Frýdek-Místek5 Jílové u Prahy5 Ostrava Poruba5 Humpolec5 Hradec Kralova5 Nový Hradec Králové5 Karvina Frystat5 Praha 4 - Krc4 Karlovy Vary4 Brno-Bohunice4 Chrudim4 Litovel4 Břeclav4 Holešov4 Brandýs nad Labem-Stará Boleslav4 Tábor4 Brno-Židenice4 Přerov4 Trutnov4 Lovosice4 Kroměříž4 Poruba4 Plzen Bory4 Hradec Králove4 Nový Jiín3 Plzen Bolevec3 Bílovec3 Ostrava-poruba3 Česká Lípa3 Sokolov3 Miroslav3 Praha Klanovice3 Jilemnice3 Ledeč nad Sázavou3 Pardubice V3 Plzen - Lochotin3 New Town3 Dolní Břežany3 Kyjov3 Nymburk2 Beroun2 Havirov - Mesto2 Ostrava-Vítkovice2 Říčany2 Bohnice2 Praha 8 - Liben2 PLZE2 Motol2 Praha 5 - Motol2 Praha 8 - Libeň2 Poděbrady2 Nové Město na Moravě2 V Uvalu 842 Vodňany2 Chrudim III2 Plzen-bory2 Bílina2 Roudnice nad Labem2 Česká Třebová2 Králová2 Rokycany2 Strakonice2 Studénka2 Vsetín2 Benesov U Prahy2 Praha 4-Krc2 Nový Jicin2 Praha 1- Mala Strana2 Janske Lazne1 Ostrava - Vítkovice1 Hradec Kralove1 Jind?ich?v Hradec1 Czechia1 Plze?1 Kladruby1 Lázně Bělohrad1 Protivín1 Brno-Královo Pole1 Severomoravsky KRAJ1 Vinohrady1 Praha 8-Liben1 Multiple Locations1 Praha 8 Liben1 Brno-Vinohrady1 Vyškov1 Vítkovice1 Plzen - Bory1 Praha 2 - Nové Město1 Milovice1 Jinočany1 Ostrava- Vitkovice1 Jindichv Hradec1 Boskovice1 Měšice1 Františkovy Lázně1 Most1 Jesenice1 Praha 9 - Klánovice1 Blansko1 Borovany1 Brněnec1 Bystřice pod Hostýnem1 Čelákovice1 Česká Kamenice1 Pragues1 Brno-Zidonice1 Lomnice1 Mohelnice1 Rudná1 Velké Popovice1 Nová Ves pod Pleší1 Bedihošť1 Nový Jicín1 Phaha 51 Praha 8- Liben1 Pardubičky1 Praha 13-stodulky1 Děčín1 Praha 2 Nove Mesto1 Benátky nad Jizerou1 Havirov-Podlesi1 Bohuslavice1 Svitavy1 Prague 8 - Liben1 Moravská Ostrava1 Liberec11 Štětí1 Čáslav1 Brno-střed1 Hradec1 Znojmo1 Písek1 Jihlavska1 Prague (Praha)1 Srobarova C1 Habry1 Praha 9 - Klanovice1 Hranice1 Plzen-Bory1 Předměstí1 Sternberk1 Vestec1 Smiřice1 Ústní Nad Labem1 Plzen - Lochotín1 Pribram VIII1 Zizkova1 Pelhřimov1 Slovany1 Vysoké Mýto1 Praha1 Plzen-Lochotin1 Šumperk1 Polička1 Hostivice1 Brandys Nad Lebem1 Hradiště1 Jindrichuv Hradec III1 Police nad Metují1 Třebíč1 Ostrova1 Brno - Sever1 Plzeň 31
All 215 locations
Target enrolment
to

Trials with a site in Ostrava

282 of 1513 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Czechia
Start
Not yet open
University Hospital Ostrava
Phase 2
200
Ostrava, Prague
2027-01
Recruiting
BTL Industries Ltd.
Not applicable
20
Ostrava
2026-10-15
Not yet open
Charles University, Czech Republic
Not applicable
306
Ostrava, Prague
2026-10
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Brno, Hradec Králové, Ostrava, Pilsen, Prague
2026-09-09
Not yet open
University Hospital Ostrava
Observational
300
Ostrava
2026-09
Recruiting
Eli Lilly and Company
Phase 3
2,001
Brno, České Budějovice, Habry, Ostrava, Prague, Praha 9 - Klanovice, Uherské Hradiště
2026-08-26
Recruiting
Novo Nordisk A/S
Phase 3
1,778
Brno, Broumov, Český Krumlov, Dolní Břežany, Hradec Králové, Náchod, Ostrava, Pardubice
2026-08-24
Recruiting
AstraZeneca
Phase 3
2,500
Benešov, Brandýs nad Labem, Brno, Hodonín, Kladno, Ostrava, Prague, Štětí
2026-08-19
Recruiting
Eli Lilly and Company
Phase 2
606
Jindichv Hradec, Miroslav, Ostrava, Prague
2026-08-07
Recruiting
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc
DrugsEtoposide·Atezolizumab·Carboplatin
SystImmune Inc.
Phase 3
550
České Budějovice, Ostrava, Ostrava-Poruba
2026-08-04
Recruiting
AstraZeneca
Phase 3
600
Broumov, České Budějovice, Ostrava, Pilsen, Prague
2026-07-08
Recruiting
AstraZeneca
Phase 3
2,000
Hradec Králové, Humpolec, Jílové u Prahy, Ostrava, Prague, Příbram
2026-07-06
Recruiting
Hoffmann-La Roche
Phase 3
380
Brno, Hradec Králové, Ostrava
2026-06-23
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
132
Ostrava, Prague
2026-06-12
Recruiting
AstraZeneca
Phase 2
80
Brno, Hradec Kralova, Ostrava
2026-06-04
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Brno, Hradec Králové, Ostrava, Plzen-Lochotin, Prague
2026-05-31
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Ostrava, Pardubice, Prague
2026-05-28
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Ostrava, Brno, Hradec Králové, Olomouc, Prague
2026-05-27
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Brno, České Budějovice, Hradec Králové, Kladno, Ostrava, Prague
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Hradec Králové, Kladno, Ostrava, Prague
2026-05-22
Recruiting
Sanofi
Phase 3
300
Hlučín, Ostrava, Prague, Uherské Hradiště, Zlín
2026-05-12
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Kroměříž, Louny, Ostrava, Ústí nad Labem, Brandýs nad Labem, Brno, Broumov, Chlumec nad Cidlinou
2026-05-11
Recruiting
Orthopedic Procedures and Postoperative Delirium in Older Adults in the Czech Republic
NCT07432009Frailty, Cognitive Impairment, Older Adults, Hip Arthroplasty
Tomas Bata Hospital, Czech Republic
Observational
400
Brno, Olomouc, Ostrava, Prague, Vsetín, Zlín
2026-04-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Brno, Ostrava, Hradec Králové, Olomouc, Prague
2026-04-09
Recruiting
Hyperbaric Oxygen Therapy in Complex Regional Pain Syndrome
NCT07446712Chronic Pain, Complex Regional Pain Syndrome
University Hospital Ostrava
Not applicable
60
Ostrava
2026-04-01
Recruiting
Sanofi
Phase 2/3
526
Ostrava, Prague
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 3
750
Ostrava, Pilsen, Hradec Králové, Olomouc
2026-03-12
Recruiting
Takeda
Phase 3
1,182
Ostrava, Pardubice, Prague, Uherské Hradiště, Zlín
2026-03-11
Active, closed
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Ostrava, Prague
2026-03-03
Active, closed
Pfizer
Phase 3
1,078
Brandys Nad Lebem, Náchod, Ostrava, Pardubice, Prague
2026-02-24
Recruiting
Eli Lilly and Company
Phase 3
900
Brno, Ostrava, Pardubice, Uherské Hradiště
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
300
Jihlava, Ostrava, Prague
2026-02-05
Recruiting
On Scene ECPR in Ostrava
NCT07374289Cardiac Arrest (CA), Cardiogenic Shock
University Hospital Ostrava
Not applicable
90
Ostrava
2026-01-30
Recruiting
BeOne Medicines
Phase 3
500
Brno, Hradec Králové, Olomouc, Ostrava, PLZE, Prague
2026-01-22
Active, closed
CSL Behring
Phase 2
84
Brno, Ostrava, Prague
2026-01-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Brno, Nový Jičín, Ostrava, Prague
2026-01-19
Recruiting
Servier Bio-Innovation LLC
Phase 1
30
Prague, Brno, Ostrava
2026-01-14
Recruiting
Takeda
Phase 3
183
Ostrava
2026-01-14
Recruiting
University of Ostrava
Phase 2
34
Ostrava
2026-01-12
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Brno, Olomouc, Ostrava, Pardubice, Prague
2026-01-06
Not yet open
University Hospital Ostrava
Not applicable
1,508
Ostrava, Frýdek-Místek, Havířov, Zlín
2026-01-05
Recruiting
Prevalence of Carotid Web in Youth
NCT07495241Carotid Web
University of Ostrava
Observational
829
Ostrava
2026-01-04
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Hradec Králové, Ostrava, Olomouc
2026-01-02
Recruiting
University Hospital Ostrava
Not applicable
540
Ostrava
2026-01-01
Not yet open
Comprehensive Analysis of the Swallowing Mechanism Using High-resolution Manometry With Impedance
NCT07365046Extraesophageal Reflux, Laryngopharyngeal Reflux, Dysphagia, Chronic Cough
University Hospital Ostrava
Not applicable
160
Ostrava
2026-01
Recruiting
European Myeloma Network B.V.
Phase 3
1,000
Hradec Králové, Olomouc, Ostrava, Pilsen
2025-12-23
Active, closed
Pfizer
Phase 3
3,578
Brno, Náchod, Ostrava, Pardubice, Prague
2025-12-19
Recruiting
Draig Therapeutics Ltd
Phase 2
300
Ostrava, Prague, Říčany
2025-12-16
Recruiting
Eli Lilly and Company
Phase 3
1,035
Krnov, Ostrava, Prague
2025-12-15
Recruiting
UCB Biopharma SRL
Phase 1
392
Brno, Hlučín, Ostrava, Uherské Hradiště
2025-12-10
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Hradec Králové, Olomouc, Ostrava, Prague, Zlín
2025-12-03
Recruiting
Eli Lilly and Company
Phase 3
7,140
Brandýs nad Labem, Chlumec nad Cidlinou, České Budějovice, Havířov, Jablonec nad Nisou, Jílové u Prahy, Krnov, Ostrava
2025-12-01
Recruiting
Hoffmann-La Roche
Phase 3
250
Mladá Boleslav, Ostrava, Prague
2025-11-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Brno, Ostrava, České Budějovice, Hradec Králové, Olomouc, Prague
2025-11-26
Recruiting
Pfizer
Phase 2
165
Náchod, Ostrava, Pardubice, Prague
2025-11-20
Active, closed
Novartis Pharmaceuticals
Phase 2
34
Ostrava, Brno, Prague
2025-11-10
Recruiting
Sanofi
Phase 2
208
Ostrava, Prague
2025-11-06
Active, closed
Bluefin Biomedicine, Inc.
Phase 2/3
210
Ostrava, Pardubice, Prague
2025-11-03
Not yet open
Sacral Neuromodulation in Patients With Double Incontinence
NCT07212387Double Incontinence, Faecal Incontinence, Urinary Incontinence
University Hospital Ostrava
Not applicable
30
Ostrava
2025-11
Recruiting
Eli Lilly and Company
Phase 3
4,500
Liberec, Ostrava, Prague
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
1,000
Benešov, Brno, Karlovy Vary, Náchod, Olomouc, Ostrava, Pilsen, Prague
2025-09-30
Recruiting
Pfizer
Phase 3
680
Ostrava, Brno, Nový Jičín, Olomouc, Prague
2025-09-29
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Nový Jicín, Prague, Brno, Náchod, Olomouc, Ostrava, Ústí nad Labem
2025-09-22
Active, closed
Triveni Bio
Phase 2
95
Ostrava, Pardubice, Prague
2025-08-26
Recruiting
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease
Abcentra
Phase 2
240
Ostrava, Pilsen, Prague, Brno
2025-08-11
Recruiting
AstraZeneca
Phase 3
800
Brno, Hradec Králové, Nový Jičín, Ostrava, Prague, V Uvalu 84
2025-08-01
Active, closed
Bluefin Biomedicine, Inc.
Phase 2
225
Ostrava, Pardubice, Prague
2025-07-15
Active, closed
TG Therapeutics, Inc.
Phase 3
360
Brno, Hradec Králové, Jihlava, Ostrava, Pardubice, Zlín
2025-07-09
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Brno, Ostrava, Prague
2025-07-02
Recruiting
University Hospital Ostrava
Not applicable
60
Ostrava
2025-07-01
By invitation
MoonLake Immunotherapeutics AG
Phase 3
835
Ostrava, Prague
2025-06-27
Recruiting
Eli Lilly and Company
Phase 3
350
Brno, Hradec Králové, Ostrava, Prague, Ústí nad Labem
2025-06-26
Recruiting
Eli Lilly and Company
Phase 3
290
Brno, Hradec Králové, Ostrava, Prague, Ústí nad Labem
2025-06-26
Recruiting
Pfizer
Phase 2
620
Krnov, Brno-Královo Pole, Brno-Židenice, Hradec Králové, Jaroměř, Ostrava, Přerov
2025-06-19
Recruiting
Prehospital ECPR in Moravia Silesia Region
NCT07041086Cardiac Arrest, Out-Of-Hospital
University Hospital Ostrava
Observational
100
Ostrava
2025-06-17
Recruiting
BioNTech SE
Phase 3
480
Brno, Olomouc, Ostrava, Prague
2025-06-10
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Brno, Klatovy, Ostrava, Pardubice, Prague
2025-05-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Ostrava, Nový Jičín, Prague
2025-05-22
Active, closed
Swedish Orphan Biovitrum
Phase 4
252
Brno, Ostrava, Prague
2025-05-21
Active, closed
Eli Lilly and Company
Phase 3
600
České Budějovice, Český Krumlov, Ostrava, Prague, Uherské Hradiště
2025-05-19
Recruiting
Clinical Safety and Efficacy Testing of a Medical Device Kardi Ai, an ECG Telemetry Monitoring System
NCT07018648Atrial Fibrillation (AF), Atrial Premature Complexes, Ventricular Premature Complexes, Bradycardia
KARDI AI Technologies s.r.o.
Not applicable
115
Olomouc, Ostrava
2025-05-19
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Hradec Kralova, Ostrava, Prague
2025-05-19
Active, closed
Eli Lilly and Company
Phase 3
800
České Budějovice, Český Krumlov, Ostrava, Prague, Uherské Hradiště
2025-05-15
Active, closed
Eli Lilly and Company
Phase 3
1,400
České Budějovice, Český Krumlov, Ostrava, Prague, Uherské Hradiště
2025-05-15
Recruiting
Takeda
Phase 3
225
Brno, Hradec Králové, Ostrava, Prague
2025-05-06
Recruiting
University Hospital Ostrava
Observational
100
Ostrava
2025-05-01
Recruiting
University Hospital Ostrava
Observational
80
Ostrava, Prague
2025-05-01
Recruiting
Optimization of Transport and Use of a Mobile ECMO Team in Patients With Sudden Cardiac Arrest in the Moravian-Silesian Region
NCT07009652Cardiac Arrest With Successful Resuscitation, Cardiac Arrest, Cause Unspecified
University Hospital Ostrava
Observational
100
Ostrava
2025-05-01
Recruiting
University Hospital Ostrava
Not applicable
260
Ostrava, Brno, Hradec Králové, Olomouc
2025-05-01
Active, closed
Eli Lilly and Company
Phase 3
487
Brno, Hodonín, Ledeč nad Sázavou, Ostrava, Pardubice V, Prague
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
487
Brno, Hodonín, Ledeč nad Sázavou, Ostrava, Pardubice V, Prague
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
974
Brno, Hodonín, Ledeč nad Sázavou, Ostrava, Pardubice V, Prague
2025-04-30
Recruiting
BeOne Medicines
Phase 3
250
Brno, Hradec Králové, Ostrava, Prague
2025-04-10
Active, closed
Philip Morris Products S.A.
Not applicable
290
Kralupy nad Vltavou, Olomouc, Ostrava, Prague, Varnsdorf
2025-04-02
Recruiting
Rectal Cancer CTC Trial
NCT07194616Rectal Cancer Patients
University Hospital Ostrava
Not applicable
120
Olomouc, Ostrava
2025-04-01
Recruiting
Eli Lilly and Company
Phase 3
700
Ostrava, Prague
2025-03-27
Active, closed
Amgen
Phase 3
1,105
Brno, Ostrava, Pardubice, Prague, Pribram VIII
2025-03-17
Active, closed
Amgen
Phase 3
3,853
Brandýs nad Labem, Brno, Havířov, Olomouc, Ostrava, Prague
2025-03-12
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Brno, Hradec Králové, Ostrava, Prague
2025-03-12
Recruiting
Early Detection of CTEPH in Patients After APE
NCT06865326Chronic Pulmonary Thromboembolism
Institute of Health Information and Statistics of the Czech Republic
Observational
500
Brno, Havlíčkův Brod, Hradec Králové, Jihlava, Náchod, Olomouc, Ostrava, Pardubice
2025-03-07
Recruiting
Takeda
Phase 3
1,088
Brno, Hlučín, Prague, Uherské Hradiště, Ostrava, Zlín, Pardubice
2025-03-03
Recruiting
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 3
339
Brno, Hradec Králové, Olomouc, Ostrava, Pilsen, Prague
2025-02-27
Recruiting
Bristol-Myers Squibb
Phase 3
530
Brno, Ostrava, Prague, Olomouc
2025-02-25
Active, closed
Janssen Research & Development, LLC
Phase 3
552
Brno, Brno-Židenice, Břeclav, Hlučín, Karvina Frystat, Ostrava, Prague, Uherské Hradiště
2025-02-21
Recruiting
Menarini Group
Phase 2
44
Ostrava, Prague
2025-02-18
Active, closed
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
NCT06680817Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Observational
875
Liberec, Mladá Boleslav, Olomouc, Ostrava, Prague
2025-02-05
Recruiting
AbbVie
Observational
1,200
Ostrava, Pilsen
2025-01-31
Recruiting
Ascentage Pharma Group Inc.
Phase 3
490
Brno, Hradec Králové, Ostrava, Prague
2025-01-22
Recruiting
GlaxoSmithKline
Phase 3
1,840
Jindřichův Hradec, Jinočany, Ostrava, Prague
2025-01-10
Active, closed
Immunovant Sciences GmbH
Phase 2
120
Brno, Ostrava, Praha 2 Nove Mesto, Uherské Hradiště, Zlín
2025-01-10
Active, closed
Janssen Research & Development, LLC
Phase 3
813
Brno, Břeclav, Hlučín, Ostrava, Prague, Uherské Hradiště, Zlín
2025-01-09
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Náchod, Ostrava, Prague, Brno, Kutná Hora, Nový Jičín, Olomouc, Pardubice
2025-01-08
Recruiting
Socket Preservation Using Autogenous Dentin
NCT07608289Tooth Extraction Site Healing
University of Ostrava
Not applicable
80
Ostrava
2025-01-01
Recruiting
St. Anne's University Hospital Brno, Czech Republic
Phase 2
112
Brno, Olomouc, Ostrava, Ústí nad Labem
2025-01-01
Recruiting
GlaxoSmithKline
Phase 3
520
Ostrava, Prague
2024-12-16
Active, closed
Janssen Research & Development, LLC
Phase 3
655
Brno, Karvina Frystat, Ostrava, Prague, Uherské Hradiště
2024-12-04
Active, closed
Pfizer
Phase 3
636
Brno, Hradec Králové, Ostrava, Prague
2024-11-15
Active, closed
Sanofi Pasteur, a Sanofi Company
Phase 1/2
750
Jindřichův Hradec, Ostrava, Pilsen, Prague
2024-11-05
Recruiting
University Hospital Ostrava
Not applicable
100
Ostrava
2024-11-01
Recruiting
argenx
Phase 3
69
Ostrava, Prague
2024-10-18
Active, closed
MoonLake Immunotherapeutics AG
Phase 3
960
Brno, Břeclav, Ostrava, Prague, Studénka, Zlín
2024-10-15
Active, closed
MoonLake Immunotherapeutics AG
Phase 3
600
Brno, Ostrava, Studénka, Zlín
2024-10-15
Recruiting
North Eastern German Society of Gynaecological Oncology
Phase 2
640
Ostrava, Prague
2024-10-11
Active, closed
Ipsen
Phase 2
670
Brno, Choceň, Hradec Králové, Ostrava, Pardubice, Prague
2024-10-10
Active, closed
Takeda
Phase 3
2,099
Náchod, Nový Jičín, Ostrava, Olomouc, Pardubice, Brno, Prague
2024-09-04
Not yet open
University Hospital Ostrava
Observational
100
Ostrava
2024-09-01
Recruiting
Sanofi
Phase 3
160
Brno, Hradec Králové, Ostrava, Pardubice, Prague
2024-08-21
Recruiting
NovoCure GmbH
Phase 3
734
Olomouc, Ostrava, Prague
2024-07-31
Recruiting
Stimvia s.r.o.
Not applicable
20
Ostrava
2024-07-19
Recruiting
argenx
Phase 2/3
12
Brno, Ostrava
2024-06-28
Active, closed
AbbVie
Phase 3
1,400
Ostrava, Karlovy Vary, Prague
2024-06-27
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Brno, Hradec Králové, Ostrava, Prague
2024-06-03
Active, closed
AbbVie
Phase 3
421
Brno, Ostrava, Prague, Hradec Králové
2024-05-19
Recruiting
Novartis Pharmaceuticals
Phase 3
65
Ostrava
2024-05-08
Active, closed
Sanofi
Phase 3
1,541
Kutná Hora, Nový Jičín, Olomouc, Ostrava, Pilsen, Prague
2024-05-08
Recruiting
CSL Behring
Phase 2/3
3,110
Český Krumlov, Hradec Králové, Nový Jičín, Ostrava, Prague
2024-04-27
Recruiting
AstraZeneca
Phase 3
3,850
Brno, Broumov, Česká Lípa, Jaroměř, Louny, Ostrava, Pilsen, Plzen - Bory
2024-04-12
Recruiting
Invasive Candidiasis in Critical Care
NCT06456151Invasive Candidiasis
University Hospital Ostrava
Observational
100
Ostrava, Prague
2024-04-11
Active, closed
Almirall, S.A.
Observational
42
Ostrava, Pilsen, Prague, Ústí nad Labem
2024-04-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Brno, Ostrava
2024-04-03
Active, closed
Takeda
Phase 2
213
Hořovice, Brno, Hradec Králové, Ostrava, Ostrava-Poruba, Pardubice, Prague, Ústí nad Labem
2024-03-29
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
Hoffmann-La Roche
Phase 3
1,350
Brno, Ostrava, Pilsen
2024-03-13
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Ostrava, Olomouc, Prague
2024-03-12
Active, closed
Eli Lilly and Company
Phase 3
17,300
Brandýs nad Labem, Brno, Litovel, Náchod, Olomouc, Ostrava, Prague, Říčany
2024-03-05
Recruiting
Takeda
Phase 2
268
Hořovice, Brno, České Budějovice, Hradec Králové, Ostrava, Ostrava-Poruba, Pardubice, Prague
2024-03-05
Recruiting
medac GmbH
Phase 3
277
Prague, Olomouc, Ostrava, Pardubice
2024-02-27
Active, closed
Dianthus Therapeutics
Phase 2
65
Ostrava
2024-02-23
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Ostrava, Prague
2024-02-21
Recruiting
AstraZeneca
Phase 3
5,250
Brandýs nad Labem, Jindřichův Hradec, Olomouc, Ostrava, Prague, Rokycany, Tábor
2024-02-21
Active, closed
Sanofi
Phase 3
260
Brno, Hradec Králové, Ostrava, Prague
2024-01-23
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Brno-Bohunice, Hradec Králové, Olomouc, Ostrava
2024-01-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Brno, Ostrava, Olomouc, Prague
2023-12-31
Active, closed
Sanofi
Phase 3
943
Brno, Hradec Králové, Jihlava, Ostrava, Prague, Teplice, Zlín
2023-12-27
Recruiting
Eli Lilly and Company
Phase 3
1,264
Ostrava, Prague
2023-12-21
Recruiting
PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
NCT05581121Cervical Carcinoma, Adenocarcinoma, Adenosquamous Carcinoma
Institut Claudius Regaud
Phase 3
510
Ostrava, Pilsen, Prague
2023-12-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Ostrava, Pardubice, Prague, Olomouc
2023-12-15
Active, closed
Sanofi
Phase 3
1,655
Brno, Hradec Králové, Jihlava, Ostrava, Pardubice, Prague, Teplice, Zlín
2023-12-13
Active, closed
Sanofi
Phase 2
197
Ostrava, Prague
2023-12-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Brno, Ostrava, Nový Jiín, Olomouc, Prague
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Brno, Ostrava, Olomouc, Prague
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Brno, Ostrava, Pilsen, Olomouc, Prague
2023-11-12
Active, closed
BeOne Medicines
Phase 3
652
Brno, Hradec Králové, Olomouc, Ostrava, PLZE, Prague
2023-11-11
Recruiting
University Hospital Ostrava
Observational
40
Ostrava
2023-11-01
Active, closed
Bristol-Myers Squibb
Phase 3
402
Brno, Ostrava, Prague
2023-10-24
Active, closed
Eli Lilly and Company
Phase 3
160
Olomouc, Ostrava, Prague, Jihlava
2023-10-16
Active, closed
Stichting European Myeloma Network
Phase 3
759
Brno, Králová, Ostrava, Pilsen
2023-10-10
Active, closed
Novartis Pharmaceuticals
Phase 3
109
Ostrava
2023-10-02
Recruiting
University Hospital Ostrava
Observational
3,000
Ostrava, České Budějovice
2023-10-01
Active, closed
Ipsen
Phase 3
751
Brno, Choceň, Jihlava, Ostrava, Prague
2023-09-29
Recruiting
Gilead Sciences
Phase 3
402
Ostrava, Pilsen, Prague
2023-09-07
Recruiting
Ipsen
Phase 3
276
Hradec Králové, Liberec, Ostrava, Pilsen, Prague
2023-08-31
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Brno, Hradec Králové, Ostrava, Prague
2023-08-31
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 3
2,769
Brandýs nad Labem-Stará Boleslav, Brno, Jihlava, Jindřichův Hradec, Lovosice, Ostrava, Prague, Varnsdorf
2023-08-30
Active, closed
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Observational
366
Brno, Hradec Králové, Ostrava, Teplice
2023-08-03
Active, closed
Belite Bio, Inc
Phase 3
429
Ostrava, Prague
2023-07-27
Recruiting
University Hospital Ostrava
Observational
150
Ostrava
2023-07-01
Recruiting
University Hospital Ostrava
Observational
200
Ostrava
2023-07-01
Recruiting
Early Diagnosis of Invasive Lung Aspergillosis
NCT05860387Respiratory Infection, Invasive Pulmonary Aspergillosis
University Hospital Ostrava
Observational
150
Havířov, Krnov, Ostrava, Olomouc
2023-05-31
Recruiting
The Institute of Molecular and Translational Medicine, Czech Republic
Observational
150
Ostrava
2023-05-02
Recruiting
University Hospital Ostrava
Not applicable
65
Ostrava
2023-05-02
Active, closed
Karyopharm Therapeutics Inc
Phase 3
257
Brno, Ostrava, Prague
2023-04-18
By invitation
Sanofi
Phase 2
70
Brno, Ostrava, Prague
2023-04-05
Active, closed
Sanofi
Phase 2
118
Brno, Olomouc, Ostrava, Prague
2023-04-05
Active, closed
Alfasigma S.p.A.
Phase 3
495
Prague, Brno, Ostrava, Pardubice, Uherské Hradiště, Zlín
2023-04-05
Active, closed
Sanofi
Phase 2
999
Nový Jičín, Ostrava, Prague
2023-04-03
Recruiting
University Hospital Ostrava
Not applicable
480
Liberec, Ostrava, Třinec, Olomouc, České Budějovice, Brno, Prague
2023-04-01
Recruiting
Charles University, Czech Republic
Observational
209
Ostrava, Pardubice, Prague, České Budějovice
2023-04-01
Active, closed
AbbVie
Phase 3
520
Brno, Prague, Nový Jičín, Ostrava
2023-03-15
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Louny, Ostrava, Ústí nad Labem, Přerov, Brandýs nad Labem, Brno, Chlumec nad Cidlinou, Český Krumlov
2023-03-09
Active, closed
COMPASS Pathways
Phase 3
572
Klecany, Kutná Hora, Ostrava, Pilsen, Prague
2023-02-14
Active, closed
Genmab
Phase 3
900
Brno, Hradec Králové, Ostrava, Prague
2023-02-08
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Ostrava, Prague
2023-02-03
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,564
Brno, Hradec Králové, Ostrava
2023-01-16
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Brno, Hradec Králové, Olomouc, Ostrava, Prague, Slaný
2023-01-16
Active, closed
Bristol-Myers Squibb
Phase 3
513
Ostrava, Prague
2023-01-12
Recruiting
European Myeloma Network (EMN) Sample Project
NCT06237803Multiple Myeloma, Smoldering Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Myeloma
European Myeloma Network B.V.
Observational
6,000
Havířov, Nový Jičín, Olomouc, Opava, Ostrava, Pelhřimov, Prague
2022-12-21
Active, closed
Amgen
Phase 3
7,297
Ostrava
2022-12-14
Active, closed
Dizal Pharmaceuticals
Phase 3
324
Olomouc, Ostrava
2022-12-13
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
885
Brandýs nad Labem, Hradec Králové, Louny, Náchod, Ostrava, Prague, Příbram, Teplice
2022-12-13
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2
87
Ostrava
2022-11-07
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Brno-Bohunice, Hradec Králové, Olomouc, Ostrava, Pilsen, Prague
2022-10-25
Active, closed
Eli Lilly and Company
Phase 3
15,374
Brandýs nad Labem, Český Krumlov, Havířov, Hodonín, Jindřichův Hradec, Olomouc, Ostrava, Prague
2022-10-11
Recruiting
Gastric Pathophysiology in Diabetes
NCT06068114Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Functional Dyspepsia, Gastroparesis
Institute for Clinical and Experimental Medicine
Observational
120
Ostrava, Prague
2022-10-05
Active, closed
Eli Lilly and Company
Phase 3
8,000
Brno, Hořovice, Hradec Králové, Ostrava, Pardubice, Prague
2022-10-04
Recruiting
Janssen Research & Development, LLC
Phase 2/3
201
Hradec Králové, Ostrava, Pardubice
2022-09-23
Active, closed
Janssen Research & Development, LLC
Phase 3
418
České Budějovice, Hradec Kralova, Ostrava, Prague
2022-09-13
Active, closed
European Myeloma Network B.V.
Phase 3
1,594
Hradec Králové, Olomouc, Ostrava, Pilsen, Prague
2022-09-08
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Ostrava, Brno
2022-08-30
Active, closed
Biogen
Phase 2
416
Brno, Hradec Králové, Ostrava, Prague, Rychnov nad Kněžnou
2022-08-24
Active, closed
Sanofi
Phase 2/3
1,856
Brno, Kutná Hora, Nový Jičín, Olomouc, Ostrava, Pilsen, Prague
2022-08-22
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
Brno, Hradec Králové, Ostrava, Pilsen, Prague
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsNemtabrutinib·Zilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 2
189
Brno, Ostrava, Prague
2022-07-21
Active, closed
Incyte Corporation
Phase 1/2
53
Brno, Ostrava, Prague
2022-07-19
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,546
Hradec Králové, Vinohrady, Ostrava
2022-07-14
Recruiting
University of Zurich
Phase 1
15
Ostrava
2022-07-01
Active, closed
Sanofi
Phase 3
531
Brno, Olomouc, Ostrava, Prague
2022-06-23
Active, closed
ADC Therapeutics S.A.
Phase 1
154
Ostrava, Prague
2022-06-17
Active, closed
Genmab
Phase 2
264
Brno, Ostrava, Prague, Hradec Králové
2022-06-14
Active, closed
IO Biotech
Phase 3
407
Hradec Králové, Olomouc, Ostrava, Prague
2022-05-17
Active, closed
University Hospital Ostrava
Not applicable
187
Ostrava
2022-05-02
Recruiting
Sleep Disturbances and Delirium
NCT05402280Sleep Disturbance
University of Ostrava
Not applicable
3,240
Ostrava
2022-05-01
Recruiting
FMISO-based Adaptive Radiotherapy for Head and Neck Cancer
NCT05348486Head and Neck Cancer, Hypoxia, FMISO, Dose Escalation
University Hospital Olomouc
Not applicable
120
Brno, Olomouc, Ostrava
2022-04-20
Active, closed
Pfizer
Phase 3
854
Brno, Hradec Králové, Ostrava, Olomouc, Prague
2022-03-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Brno, Ostrava, Olomouc, Prague, Hradec Králové
2022-03-15
Recruiting
Takeda
Phase 3
120
Prague, Ostrava
2022-02-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Brno, Ostrava, Nový Jiín, Olomouc, Prague, Zlín
2022-02-03
Active, closed
Eli Lilly and Company
Phase 3
152
Brno, Ostrava, Prague
2021-12-20
Active, closed
Womed
Not applicable
160
Ostrava
2021-11-29
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Ostrava, Brno, Hradec Králové
2021-10-06
Not yet open
Czech Lymphoma Study Group
Phase 2
21
Brno, Hradec Králové, Olomouc, Ostrava, Pilsen, Prague
2021-09-01
Active, closed
Janssen Research & Development, LLC
Phase 4
411
Brno, Brno-Židenice, Hlučín, Karvina Frystat, Ostrava, Pardubice, Prague, Uherské Hradiště
2021-08-30
Recruiting
Miltenyi Biomedicine GmbH
Phase 2
213
Hradec Králové, Ostrava
2021-08-18
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Ostrava, Brno
2021-07-27
Recruiting
Genentech, Inc.
Phase 1
186
Ostrava, Prague
2021-07-26
Active, closed
Bristol-Myers Squibb
Phase 3
729
Brno, Ostrava, Prague, Uherské Hradiště
2021-07-15
Active, closed
Bristol-Myers Squibb
Phase 3
670
Prague, Uherské Hradiště, Zlín, Ostrava, Pardubice
2021-07-13
Active, closed
Janssen Research & Development, LLC
Phase 3
1,054
Brno, Brno-Židenice, Hlučín, Ostrava, Pardubice, Prague, Uherské Hradiště, Zlín
2021-06-17
Active, closed
Bristol-Myers Squibb
Phase 3
681
Brno, Hradec Králové, Olomouc, Ostrava, Prague, Praha 8 Liben
2021-05-21
Active, closed
The SELUTION DeNovo Study
NCT04859985Coronary Artery Disease
M.A. Med Alliance S.A.
Not applicable
3,326
Brno, Ostrava
2021-05-15
Active, closed
Incyte Corporation
Phase 3
899
Brno, Hradec Králové, Olomouc, Ostrava, Prague
2021-05-11
Recruiting
Ipsen
Phase 1/2
240
Hradec Králové, Jihlava, Ostrava, Pardubice, Prague
2021-04-29
Active, closed
Incyte Corporation
Phase 3
654
Brno, Hradec Králové, Ostrava, Prague
2021-04-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Brno, Nový Jičín, Ostrava, Olomouc, Prague
2021-04-14
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
DrugsNavtemadlin·Acalabrutinib
Kartos Therapeutics, Inc.
Phase 1/2
84
Nový Hradec Králové, Ostrava, Prague
2021-02-23
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Ostrava, Brno-Zidonice, Brno, Hradec Králové, Prague, Uherské Hradiště
2020-12-22
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Hořovice, Olomouc, Ostrava, Prague, Praha 8 - Liben
2020-12-02
Active, closed
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
DrugsEpcoritamab·Pirtobrutinib·Lenalidomide·Venetoclax
Genmab
Phase 1/2
194
Brno, Olomouc, Prague, Hradec Králové, Ostrava
2020-11-25
Active, closed
European Myeloma Network B.V.
Phase 3
302
Brno, Nový Hradec Králové, Ostrava, Prague
2020-09-25
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Ostrava, Prague
2020-09-16
Active, closed
AbbVie
Phase 3
531
Brno, Hradec Králové, Ostrava, Pilsen, Prague
2020-09-10
Recruiting
Morten H. Bestle
Phase 4
1,000
Ostrava, Pilsen, Prague
2020-08-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Brno, Ostrava, Prague, Nová Ves pod Pleší, Liberec
2020-07-06
Active, closed
Eli Lilly and Company
Phase 3
996
Brno, Hradec Králové, Náchod, Olomouc, Ostrava, Prague, Zlín, Ústí nad Labem
2020-06-22
Active, closed
Masaryk University
Phase 2
150
Brno, Hradec Králové, Olomouc, Ostrava, Pilsen, Prague
2020-06-16
Recruiting
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
NCT04256317Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
DrugsVenclexta·Azacitidine·Venetoclax
Taiho Oncology, Inc.
Phase 2/3
316
Ostrava, Prague
2020-05-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
755
Brno, Ostrava, Hradec Králové, Olomouc, Prague
2020-02-27
Active, closed
rTMS Add on Value for Amelioration of Negative Symptoms of Schizophrenia
NCT04318977Negative Symptoms With Primary Psychotic Disorder, Schizophrenia
University of Regensburg
Not applicable
62
Brno, Ostrava
2020-02-01
Active, closed
BeOne Medicines
Phase 3
955
Brno, Hradec Králové, Olomouc, Ostrava, Prague
2020-01-16
By invitation
Rigel Pharmaceuticals
Phase 3
90
Brno, Ostrava
2019-10-30
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
České Budějovice, Havířov, Hradec Kralova, Olomouc, Ostrava, Prague, Strakonice
2019-09-26
Active, closed
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
NCT03992404Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
DrugXeomin
Merz Pharmaceuticals GmbH
Phase 3
603
Brno, Ostrava, Pardubice
2019-09-16
Recruiting
University Hospital Ostrava
Observational
100
Ostrava
2019-06-01
Active, closed
European Myeloma Network B.V.
Phase 2
401
Hradec Králové, Olomouc, Ostrava, Pilsen, Prague
2019-04-16
Active, closed
Institut de Recherches Internationales Servier
Phase 3
856
Brno, Ostrava, Prague
2019-03-21
Active, closed
Stichting European Myeloma Network
Phase 3
709
Ostrava
2018-12-14
Active, closed
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 2
58
Brno, Ostrava
2018-11-19
Active, closed
AbbVie
Phase 3
265
Brno, Hradec Králové, Ostrava, Olomouc, Prague
2018-10-22
Active, closed
AstraZeneca
Phase 3
1,246
Brno, Hradec Králové, Olomouc, Ostrava, Prague
2018-09-27
Active, closed
AstraZeneca
Phase 3
730
Brno, Olomouc, Ostrava, Prague
2018-09-27
Active, closed
AbbVie
Phase 3
1,242
Brno, Ostrava, České Budějovice, Hradec Králové
2018-08-28
Recruiting
University Hospital Ostrava
Observational
150
Ostrava
2018-05-01
Active, closed
Janssen Research & Development, LLC
Phase 3
211
Brno, Hradec Králové, Ostrava, Pilsen, Prague
2018-04-17
Active, closed
AbbVie
Phase 3
747
České Budějovice, Hradec Králové, Ostrava, Prague
2018-03-21
Active, closed
Gilead Sciences
Phase 3
340
Ostrava
2017-12-12
Active, closed
Eli Lilly and Company
Phase 3
5,637
Hořovice, Brno, Ostrava, Pardubice, Prague, Pilsen
2017-07-12
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
146
Ostrava
2017-06-26
Recruiting
University Hospital Ostrava
Not applicable
40
Ostrava
2017-05-25
Active, closed
AbbVie
Phase 3
443
Brno, Hradec Králové, Ostrava, Pilsen
2017-02-02
Active, closed
AbbVie
Phase 3
950
Prague, Hradec Králové, Olomouc, Ostrava, Pardubice
2017-01-31
Active, closed
AbbVie
Phase 3
1,629
Hlučín, Olomouc, Prague, Brno, Bruntál, Kladno, Ostrava, Pardubice
2015-12-01
Active, closed
AbbVie
Observational
1,446
Hradec Králové, Ostrava, Olomouc, Prague, Ústí nad Labem
2014-08-28
Recruiting
University Hospital, Gasthuisberg
Observational
5,000
Ostrava, Prague
2005-08
Rows per page Showing 1–282 of 282
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Czech investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-czechia/city/ostrava

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Czechia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,513 studies in total at the last sync on 11 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 282 of those studies with a site in Ostrava.

How many clinical trials are recruiting in Ostrava?

139 of the 282 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:18 UTC sync. A further 8 have not yet opened recruitment, 132 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ostrava), 282 studies
PhaseStudiesRecruitingShare
Phase 31697159.9%
Phase 2361512.8%
Observational27219.6%
Not applicable25168.9%
Phase 2/31073.5%
Phase 1541.8%
Phase 1/2521.8%
Phase 4531.8%

Most active sponsors

Lead sponsors with the most studies (Ostrava)
Lead sponsorStudiesRecruiting
University Hospital Ostrava2922
Eli Lilly and Company2512
Janssen Research & Development, LLC167
Merck Sharp & Dohme LLC167
Sanofi144
AbbVie121
Novartis Pharmaceuticals125
AstraZeneca97
Bristol-Myers Squibb94
Pfizer84
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.